stoxline Quote Chart Rank Option Currency Glossary
  
Aridis Pharmaceuticals, Inc. (ARDS)
0.0002  0 (0%)    05-23 16:00
Open: 0.0002
High: 0.0002
Volume: 5,000
  
Pre. Close: 0.000199999995
Low: 0.0002
Market Cap: 0(M)
Technical analysis
2025-05-23 4:46:00 PM
Short term     
Mid term     
Targets 6-month :  0 1-year :  0
Resists First :  0 Second :  0
Pivot price 0
Supports First :  0 Second :  0
MAs MA(5) :  0 MA(20) :  0
MA(100) :  0 MA(250) :  0
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  33.3 D(3) :  11.1
RSI RSI(14): 99.9
52-week High :  0.07 Low :  0
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ARDS ] has closed Bollinger Bands are 4900% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0 - 0 0 - 0
Low: 0 - 0 0 - 0
Close: 0 - 0 0 - 0
Company Description

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Headline News

Fri, 20 Dec 2024
Aridis Provides Corporate Update - GlobeNewswire

Fri, 20 Dec 2024
Aridis Pharma Secures $6.5M Asset Deal for AR-501, Advances Phase 3 Investment Plans - Stock Titan

Fri, 28 Jun 2024
Aridis Pharmaceuticals CEO buys $50,000 in company stock - Investing.com

Mon, 24 Jun 2024
Aridis Provides Corporate Update - Yahoo Finance

Wed, 12 Jul 2023
Aridis’ AR-301 Monoclonal Antibody is Among the First - GlobeNewswire

Tue, 11 Oct 2022
Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study - Nasdaq

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
OTC
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 45 (M)
Shares Float 37 (M)
Held by Insiders 18 (%)
Held by Institutions 10.3 (%)
Shares Short 2,000 (K)
Shares Short P.Month 440 (K)
Stock Financials
EPS -0.16
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.26
Profit Margin -5.2 %
Operating Margin -208.4 %
Return on Assets (ttm) -4.5 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 4.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.5
EBITDA (p.s.) -0.01
Qtrly Earnings Growth 0 %
Operating Cash Flow -18 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.01
Price to Sales 0
Price to Cash Flow -0.01
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android